A large global biopharma, with marketed assets in lung cancer and near term expected approval in GI cancers, sought to identify an optimal commercialisation partner for near-term synergies to generate immediate revenue
The client wanted a third-party review & validation to find the optimal asset (marketed or near approval). They sought asset opportunities that offered the optimal strategic benefit for both parties
We undertook a search and evaluation process to identify assets in areas/phases of interest and screened for the asset’s scientific/clinical and commercial opportunities and risks. We supplemented the assessment with secondary & primary research, leveraging our deep understanding of the area
Our team strategically guided the large biopharma to key assets and companies, and enabled the client to have better informed interactions at major medical and partnering conferences
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today
Contact us
